Hypertension: Pathophysiology, Risk Factors, Targets, and Evidence-Based Management to Prevent Cardiovascular Events

Hypertension, commonly called high blood pressure, is a chronic condition in which arterial pressure is persistently elevated, increasing the workload on the heart and the stress placed on blood vessels. Clinically, it is defined by repeated measurements showing systolic blood pressure (SBP) ≥ 130 mmHg and/or diastolic blood pressure (DBP) ≥ 80 mmHg using standardized techniques. In many individuals, hypertension is “primary” or essential, meaning no single cause is identified, and multiple interacting pathways contribute. These pathways include sympathetic nervous system overactivity, impaired baroreflex sensitivity, dysregulation of the renin-angiotensin-aldosterone system (RAAS), vascular endothelial dysfunction with reduced nitric oxide bioavailability, oxidative stress, chronic low-grade inflammation, and structural remodeling of small arteries.

Blood pressure regulation depends on coordinated renal sodium handling, vascular tone, and neurohormonal signaling. When RAAS is chronically activated, angiotensin II promotes vasoconstriction and aldosterone-mediated sodium and water retention, raising intravascular volume. Sympathetic activation increases heart rate and peripheral resistance. Endothelial dysfunction impairs vasodilation and favors a pro-thrombotic, pro-inflammatory state that accelerates atherosclerosis. Over time, the vascular smooth muscle and extracellular matrix undergo remodeling (e.g., increased stiffness), which sustains higher systolic pressures and widens pulse pressure in older adults.

Hypertension is often asymptomatic, which creates a major risk of delayed diagnosis and sustained target-organ damage. Persistently elevated pressure injures the endothelium and promotes medial hypertrophy in arterioles, leading to reduced luminal diameter and higher resistance. Target organs most vulnerable include the brain (stroke and cognitive decline), heart (left ventricular hypertrophy, heart failure, ischemic heart disease), kidneys (chronic kidney disease), and eyes (hypertensive retinopathy). Mechanistically, the combination of mechanical stress, inflammation, and metabolic derangements contributes to both microvascular dysfunction and macrovascular events.

Major risk factors include increasing age, family history, excess dietary sodium, low potassium intake, obesity and insulin resistance, sedentary lifestyle, tobacco use, harmful alcohol consumption, obstructive sleep apnea, chronic kidney disease, diabetes, dyslipidemia, and chronic stress. Secondary hypertension should be considered when blood pressure is severe, resistant to therapy, or associated with suggestive features. Common secondary causes include renal parenchymal disease, renovascular disease, primary aldosteronism, thyroid disorders, pheochromocytoma, Cushing syndrome, and medication-induced or substance-induced hypertension (for example, nonsteroidal anti-inflammatory drugs, decongestants, glucocorticoids, stimulants, and excess licorice).

Diagnosis requires correct measurement. Patients should rest quietly, avoid caffeine and nicotine for a period before measurement, use an appropriately sized cuff, and obtain multiple readings. Ambulatory blood pressure monitoring or home blood pressure monitoring can confirm diagnosis, evaluate white-coat hypertension, and identify masked hypertension. Risk stratification considers coexisting conditions and degree of elevation to guide the intensity of therapy.

Treatment follows a stepwise, evidence-based approach that combines lifestyle intervention with pharmacotherapy when indicated. Lifestyle changes with robust outcome data include sodium reduction, weight loss in overweight individuals, regular aerobic activity, moderation of alcohol, dietary patterns rich in fruits, vegetables, and low-fat dairy (e.g., DASH-type diets), and adequate dietary potassium when appropriate. Smoking cessation and management of sleep apnea can improve cardiovascular risk and, in some cases, blood pressure control.

First-line medications typically include thiazide(-like) diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers. Selection depends on comorbidities and contraindications: for example, RAAS inhibitors are often favored in the presence of diabetes with albuminuria or chronic kidney disease, while specific agents may be chosen based on heart failure type or other clinical factors. Resistant hypertension—blood pressure remaining above goal despite adherence to three appropriately dosed drugs including a diuretic—requires reassessment for measurement error, secondary causes, medication interactions, and adherence barriers. For persistent cases, mineralocorticoid receptor antagonists and other add-on agents may be considered under specialist guidance.

Treatment targets generally aim for SBP < 130 mmHg for many nonpregnant adults, balancing benefits with risks such as dizziness, falls, and electrolyte abnormalities. Special populations require individualized goals, including frail older adults, those with orthostatic hypotension, and patients with specific comorbidities. Continuous follow-up is essential to monitor efficacy, side effects, renal function, and electrolytes—particularly with diuretics and RAAS inhibitors. Because hypertension often appears “out of nowhere” in everyday conversation, it can be mistakenly attributed to single lifestyle missteps. In reality, it is frequently the cumulative result of long-term physiologic strain: repeated exposure to high sodium diets, inactivity, weight gain, stress-related autonomic shifts, poor sleep, and genetic susceptibility. Understanding hypertension as a chronic vascular disease helps patients and clinicians prioritize prevention, early detection, and sustained evidence-based management rather than short-term reactions. Source: StealthSteppin